Curebus (CEO Seong-jin Cho), a research institute company located in Hongneung Special Economic Zone, announced on February 2 that it has appointed Dr. Alex Oh as Chief Development Officer (CDO).
Alex Oh, Chief Development Officer, is a specialist with over 18 years of clinical development and operations experience in the global pharmaceutical and biotechnology industries. He has led clinical strategy development and multinational clinical operations at companies such as Sanofi, Labcorp Drug Development, Everest Medicines, and NeoImmuneTech. He also possesses hands-on experience across the entire clinical landscape, including global and Asian multi-center clinical trial execution, regulatory compliance, CRO and vendor management, and budget, quality, and schedule control.
Cureverse is rapidly entering the clinical phase of its main pipeline. CV-01 is undergoing Phase 1 clinical trials in Korea, and CV-02 has received Investigational New Drug (IND) approval for Phase 1 clinical trials from the US Food and Drug Administration (FDA) and is expected to commence clinical trials soon. Consequently, the company is entering a phase of simultaneously operating and managing multiple clinical trials both domestically and internationally, increasing the importance of clinical strategy and operations.
This CDO appointment was made to strengthen organizational capabilities, unifying everything from clinical strategy formulation to operation and execution, and increasing the speed and likelihood of success of clinical development.
CEO Cho Seong-jin said, “With CV-01 and CV-02 entering the clinical stage simultaneously, the importance of clinical operations and strategy is increasing,” and “CDO Alex Oh is a talented individual with understanding of the global clinical environment and execution experience, and we expect him to strengthen our clinical competitiveness.”
- See more related articles
You must be logged in to post a comment.